This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden.
SPCs are used in European Union and select others to encourage pharmaceutical innovation by
compensating for the long time needed to obtain regulatory approval for drugs. SPCs
come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.
The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention
may be obtained by responding to a request for pediatric trials.
For a different perspective, see the drug companies with SPCs in the most countries
The pharma companies with the most SPCs in Sweden are:
- Gilead Sciences Inc
- Janssen Prods
- Novartis
- Boehringer Ingelheim
- Viiv
- Astrazeneca
- Merck Sharp Dohme
- Abbvie Inc
- Allergan
- Bristol-myers Squibb
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
